Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ONS
Oncology Nurse Practice: Exemplars in Assuring Safety in Clinical Implementation of Treatment Innovations in Melanoma
Read More
Utilizing Nursing Handoff Communication to Manage Immune-Related Adverse Events in an Outpatient Immunotherapy Clinic
Read More
Leveraging Technology to Optimize the Care of Patients Treated with Immunotherapy
Read More
Combination Therapy in Patients with Metastatic Melanoma, NSCLC, and RCC
Read More
Overcoming HER2/ER Crosstalk: Neratinib Alone or in Combination with Fulvestrant in ER-Positive, HER2-Mutant Metastatic Breast Cancer in the Phase 2 SUMMIT Trial
Read More
Mechanism of Action of Neratinib: An Irreversible Pan-HER Inhibitor in Late-Stage Clinical Development
Read More
1
2
Page 2 of 2
Results 11 - 16 of 16